对复发的扩散B细胞淋巴瘤进行整合性放射治疗的结果
Geovanne Pedro Mauro1,2, Mario Ribeiro Neto1,2, Heloisa de Andrade Carvalho1,2
1Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
概括
放射治疗对于复发性扩散性大B细胞淋巴瘤 (DLBCL) 是一种有价值的治疗方法,特别是当自身干细胞移植 (ASCT) 不是一个选择时. 这种方法耐受性很好,在临床试验中需要进一步调查.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 辐射瘤学 辐射瘤学
背景情况:
- 复发性扩散性大B细胞淋巴瘤 (DLBCL) 是一个重大的死亡率挑战.
- 自主干细胞移植 (ASCT) 是一种标准的,但往往不可行的治疗选择.
研究的目的:
- 评估放射治疗对复发性DLBCL患者的救援治疗的影响.
- 评估放射治疗的作用,当ASCT是不可行的.
主要方法:
- 在2010年至2017年期间治疗的62名复发DLBCL患者的回顾性分析.
- 患者接受了救援治疗,其中一些包括放射治疗.
- 接受放射治疗的患者和没有接受放射治疗的患者之间的结局比较.
主要成果:
- 放射治疗被用于救援治疗24.8%的患者复发DLBCL.
- 两组之间没有观察到总体存活率或无进展存活率的显著差异.
- 放射治疗更频繁地用于那些没有在第一线接受R-CHOP的患者.
结论:
- 放射治疗在治疗复发性DLBCL中起作用,特别是当ASCT不是一种选择时.
- 涉及放射治疗的治疗方法被很好地容忍.
- 需要进行进一步的临床试验,以充分确定放射治疗在这种患者群体中的疗效.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.1K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...